H. Dastani

发表

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

M. Kudo, A. El-Khoueiry, B. Sangro, 2017, The Lancet.

Use of an Online Community to Develop Patient-Reported Outcome Instruments: The Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)

Paul Wicks, Michael Massagli, M. Massagli, 2011, Journal of medical Internet research.

Barriers to counseling patients with obesity: a study of Texas community pharmacists.

Carolyn M. Brown, H. Dastani, Carolyn M Brown, 2006, Journal of the American Pharmacists Association : JAPhA.

Combating the Obesity Epidemic: Community Pharmacists Counseling on Obesity Management

Carolyn M. Brown, H. Dastani, Carolyn M Brown, 2004, The Annals of pharmacotherapy.

High-risk patients with hypertension: Are we doing enough?

B. Nightengale, H. Dastani, J. Sobolski, 2008, Journal of the American Society of Hypertension : JASH.

Quality of life in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus in CheckMate 025, a randomised, phase 3 clinical trial

R. Motzer, D. Cella, H. Dastani, 2017 .

Treatment Patterns, Complications, and Disease Relapse in a Real-world Population of Patients with Moderate-to-severe Ulcerative Colitis Initiating Immunomodulator Therapy

H. Dastani, K. Davis, E. Loftus, 2014, Inflammatory bowel diseases.

Is Enough Being Done to Control Hypertension? An Evaluation of Blood Pressure Control Patterns in a Community‐Based Setting

H. Dastani, R. Rocha, Shadi S. Saleh, 2009, Journal of clinical hypertension.

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.

R. Motzer, D. Cella, H. Dastani, 2016, The Lancet. Oncology.

Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis

H. Dastani, R. McQueen, K. Nair, 2011, Expert review of neurotherapeutics.

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

A. Abernethy, K. Savage, P. Ascierto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study.

A. Norden, H. Dastani, M. Botteman, 2019, Neuro-oncology practice.

Assessment of drug utilization patterns, medication compliance and physician adherence to lipid and safety monitoring guidelines among patients on lipid-lowering drugs in the Texas Medicaid system

H. Dastani, 2005 .

The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.

H. Dastani, J. Menzin, L. Boulanger, 2008, Respiratory medicine.

The direct medical costs of undiagnosed chronic obstructive pulmonary disease.

H. Dastani, S. Robinson, E. Lydick, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy.

H. Dastani, G. Hess, P. Chaudhari, 2008, P & T : a peer-reviewed journal for formulary management.

460PEvaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017

H. Dastani, R. Gralla, J. Penrod, 2015 .

An Overview of Four Nonpharmacologic Complementary and Alternative Medicine Modalities

H. Dastani, W. Siganga, 2002 .

Impact of Nivolumab versus Docetaxel on Health‐Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study

H. Dastani, R. Gralla, J. Penrod, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057

H. Dastani, R. Gralla, J. Penrod, 2016 .

Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.

H. Dastani, R. Gralla, J. Penrod, 2018, European journal of cancer.

Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis

Stephen M. Rao, H. Dastani, K. Fahrbach, 2013, BMC Neurology.

Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis.

H. Dastani, J. Romley, D. Goldman, 2012, The American journal of managed care.

PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057.

H. Dastani, R. Gralla, J. Penrod, 2016, Journal of Thoracic Oncology.

Treatment Patterns, Complications, and Disease Relapse in a Real-world Population of Patients with Moderate-to-severe Ulcerative Colitis Initiating Immunomodulator Therapy

H. Dastani, K. Davis, E. Loftus, 2014, Inflammatory bowel diseases.

Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.

R. Motzer, D. Cella, H. Dastani, 2016 .